Vishal Manik

ORCID: 0000-0003-0188-4509
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Radiomics and Machine Learning in Medical Imaging
  • Advanced Radiotherapy Techniques
  • Radiopharmaceutical Chemistry and Applications
  • Childhood Cancer Survivors' Quality of Life
  • Radiation Dose and Imaging
  • Economic and Financial Impacts of Cancer
  • Cancer Treatment and Pharmacology
  • Head and Neck Cancer Studies
  • Child and Adolescent Health
  • Cancer Genomics and Diagnostics
  • Genomics and Rare Diseases
  • Hormonal and reproductive studies
  • Prostate Cancer Treatment and Research
  • Oral and Maxillofacial Pathology
  • Lung Cancer Diagnosis and Treatment
  • Meningioma and schwannoma management
  • Pituitary Gland Disorders and Treatments
  • Salivary Gland Tumors Diagnosis and Treatment
  • Ear and Head Tumors
  • Sexual Differentiation and Disorders
  • Cancer survivorship and care
  • Lanthanide and Transition Metal Complexes
  • Medical Imaging Techniques and Applications

Guy's and St Thomas' NHS Foundation Trust
2022-2024

London Cancer
2023

St. Thomas Hospital
2023

Tata Memorial Hospital
2018

Objective/Hypothesis Extranodal extension (ENE) is an independent prognosticator in head–neck Squamous cell carcinoma (SCC). All patients with ENE, however, do not behave the same, and there a need for further risk stratification. This study evaluates prognostic significance of various grades ENE number nodes on overall survival (OS) oral cavity SCC (OCSCC). Study Design Retrospective cohort study. Methods Ninety‐four node‐positive OCSCC treated primary surgery appropriate adjuvant therapy...

10.1002/lary.27508 article EN The Laryngoscope 2018-11-13

This study aimed to assess the outcome of cancer patients undergoing systemic anti-cancer treatment (SACT) at our centre help inform future clinical decision-making around SACT during COVID-19 pandemic.Patients receiving least one episode for solid tumours Guy's Cancer Centre between 1 March and 31 May 2020 same period in 2019 were included study. Data collected on demographics, tumour type/stage, type (chemotherapy, immunotherapy, biological-targeted) SARS-CoV2 infection.A total 2120...

10.3390/cancers14020266 article EN Cancers 2022-01-06

Abstract BACKGROUND IDH wildtype Glioblastoma multiforme (GBM) is an aggressive primary brain tumour. Despite treatment with surgical resection, radiotherapy (± chemotherapy) and adjuvant chemotherapy median survival remains poor. Antibiotics influence the human microbiota alter efficacy in other tumours. This study addresses antibiotic exposure GBM. MATERIAL AND METHODS A retrospective observational based on electronic patient records March 2016-May 2022 a large UK tertiary centre (N=234)...

10.1093/neuonc/noae144.319 article EN Neuro-Oncology 2024-10-01

Abstract BACKGROUND Stereotactic radiosurgery(SRS) is an established treatment for local control of intracranial (IC) metastatic disease. Clinical trials under-represent older people. Older patients may have complex additional co-morbid conditions. This study addresses SRS brain metastases in patients. MATERIAL AND METHODS Retrospective observational ≥75 years receiving IC disease November 2017-November 2023(N=96). Patients were treated at a single tertiary centre the UK with Linac-based...

10.1093/neuonc/noae144.311 article EN Neuro-Oncology 2024-10-01

Abstract BACKGROUND Glioblastoma multiforme (GBM) portends poor prognosis despite multiple attempts at finding newer therapies. The current standard of care remains maximal safe resection. 5-ALA guidance helps to maximise the resection extent but complete removal is not always possible. It unclear, if residual pattern can predict outcome patients with GBM. MATERIALS & METHODS Patients GBM treated our centre between January 2018 - July 2019 were included they had based tumour excision...

10.1093/neuonc/noae144.369 article EN Neuro-Oncology 2024-10-01

Abstract AIMS Review of a single person case study to establish if personal trainer (PT) could help build personalised pro- gramme for people with brain tumours going through oncology treatment. The aim being manage resilience both physically and psychologically treatment improve quality life. METHOD A young who has completed radiotherapy chemotherapy after surgical debulking tumour was contacted. He worked as PT before diagnosis continued throughout gradually increased his exercise...

10.1093/neuonc/noad147.094 article EN Neuro-Oncology 2023-09-16

Abstract AIMS The aim of this review is to analyse the need for a specialist nurse role TYA patients. Having new dedicated developmental implemented can help by identifying areas improvement from wider team ensure optimal support patient group. METHOD Clinic attendance over 1-year period has been measured. Looking specifically at patients who did not attend (DNA) appointments in monthly joint surgical and oncology clinic. We have evidence engaging age group with creation led weekly telephone...

10.1093/neuonc/noad147.086 article EN Neuro-Oncology 2023-09-16

Abstract AIMS The case study review will evaluate whether patients on long term steroid would benefit from calcium supplements and if a protocol for bone density scan should be in place relation to how have been steroids for. Duration of use increases patients’ risk related toxicity when taken more than 3 weeks. These can include endocrine, skeletal psychiatric side effects amongst many others. It is therefore important assess we improve quality life (QOL) with limited prognosis. METHOD In...

10.1093/neuonc/noad147.085 article EN Neuro-Oncology 2023-09-16

Abstract AIMS Whole genome sequencing is currently being offered to paediatric, teenage and young adult neuro-oncology patients this was managed by a genomics practitioner who works cross-site. We found that some are discharged from the hospital without 1 component of test or consent. Our aim create solid pathway in which fresh tissue, blood sample record discussion taken at certain stage their admission. METHOD A poster created remind theatre team tumour tissue EDTA required samples proceed...

10.1093/neuonc/noad147.087 article EN Neuro-Oncology 2023-09-16

Abstract AIMS Brain metastases from gastrointestinal primaries are uncommon with poor reported outcomes following SRS. We evaluated clinical for patients diagnosed metastatic brain tumours a primary treated stereotactic radiosurgery (SRS). METHOD A single institutional retrospective review of LINAC-based SRS at our institution between 2017 and 2022. Median survival was calculated the time RESULTS total 24 were malignancy locations as follows: 10 colon, 7 rectum oesophageal. 6.4 months...

10.1093/neuonc/noad147.089 article EN Neuro-Oncology 2023-09-16

Abstract BACKGROUND/OBJECTIVE Central nervous system (CNS) haemangiopericytomas (HPC) or solitary fibrous tumours (SFT) are rare aggressive tumours. Surgery is the primary modality of treatment, however, often followed by postoperative radiotherapy due to high tendency for local recurrence. Although rare, extracranial metastases several sites have been described. We aim report our institutional experience in managing these METHODS Patients with central HPC/SFT who underwent surgical...

10.1093/neuonc/noad179.0223 article EN Neuro-Oncology 2023-11-01

Abstract BACKGROUND A single centre retrospective review of outcomes following linear accelerator - based stereotactic radiosurgery (SRS) for patients with 6 to 18 brain metastases was conducted. METHODS Patients receiving SRS multiple metastatic sites were identified from our institutional database and subsequently stratified into those 6-9 (group 1) 10 or more 2). RESULTS 45 evaluated in total a mean number 7 group 1 14 2. Mean GTV volumes each treatment 1.92cc 2.70cc Median overall...

10.1093/neuonc/noad179.0206 article EN Neuro-Oncology 2023-11-01

Abstract Background Recurrent high grade gliomas (HGG) pose a treatment challenge as no definite guidelines exist. Re-excision could be appropriate in some cases while systemic therapy options are only handful. We thus need to resort the option of re-irradiation at point but there wide variety techniques, volumes & doses choose from due lack robust evidence. The UK BRIOCHe study for Glioblastoma Multiforme (GBM) will help providing standardisation. With this retrospective study, we aim...

10.1093/neuonc/noac174.316 article EN Neuro-Oncology 2022-09-01

Abstract AIM Not uncommonly, we come across significantly large high grade glioma cases (HGGs). With standard delineation protocols, end up irradiating a volume of normal brain. Emami & QUANTEC data define brain tolerance doses, however they are often limited use in clinic practice. Thus, reviewed our patients with significant tumor volumes to derive safe dose/ level for METHODOLOGY Patients HGGs over the last 3 years were extracted from Mosaiq™ information system. The output was sorted...

10.1093/neuonc/noab196.178 article EN Neuro-Oncology 2021-11-02
Coming Soon ...